Search the Community

Copied as found. Don't know how true this is. APRIL 10, 2020 On Wednesday, the U.S. Food and Drug Administration issued a statement regarding an experimental treatment for COVID-19. It involved “convalescent plasma” collected from people who have recovered from the disease. The FDA said that, while the treatment had not been approved (since experimental data was virtually non-existent), there were a few places where scientists or doctors could use it, including in patients with “serious or immediately life-threatening COVID-19 infections.” The thinking is that there are antibodies present in the plasma of recovered patients that could help current patients fight the virus. Okay. Fine. The problem is that the Jehovah’s Witnesses are reacting to this statement by saying it would violate the religion’s rules to accept this treatment. JWs have famously refused blood transfusions since 1945 even when they’re needed to save their own lives. The religion’s leaders are now saying plasma is included in that ban. The watchdog site JWsurvey obtained a “leaked memo from a Jehovah’s Witness Circuit Overseer” sent to local leaders: Do you think ALMIGHTY GOD really means this ?

If a Brother or Sister in good standing in the Congregation goes into the hospital, and agrees to a whole blood transfusion, and dies anyway, can they be disfellowshipped post mortem, and what about the funeral arrangements? ( I have heard of this being done, but never explained....) Can they have a funeral at the Kingdom Hall? Let's say a Brother or Sister in good standing in the Congregation goes berserk, and commits some crime, and either dies by misadventure, or gets shot by police .... Can they have a funeral at the Kingdom Hall? Considering such questions is like a submarine on the surface, at night, in the fog .... firing torpedoes randomly into the darkness, to see what lights up. .... sometimes survival depends on having the right answer about "What is out there?".

Iron overload is a potentially life-threatening consequence of multiple red-blood-cell transfusions. Here, we review factors affecting excess iron distribution and its damage to specific tissues, as well as mechanisms of oncogenesis by iron. Although consequences of transfusional iron overload are best described in thalassemia major and related inherited anemias, they are increasingly recognized in acquired conditions, such as myelodysplastic syndromes (MDS). Iron overload in MDS not only impacts on certain tissues, but may affect the clonal evolution of MDS through generation of reactive oxygen species. Iron overload may also influence hematopoietic-stem-cell-transplantation outcomes. Novel MRI methods for assessing body iron have impacted significantly on outcome in inherited anemias by allowing monitoring of iron burden and iron chelation therapy. This approach is increasingly being used in MDS and stem-cell-transplant procedures. Knowledge gained from managing transfusional iron overload in inherited anemias may be translated to general oncology, with potential for improved patient outcomes. Copyright © 2016. Published by Elsevier Ireland Ltd. Source: http://www.ncbi.nlm.nih.gov/pubmed/26806144?platform=hootsuite